Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$2.25 -2.8%	$2.66	$1.83 ▼ $7.48	$2.12B	0.12	7.87 million shs	6.49 million shs
IRON Disc Medicine	$59.47 -1.5%	$56.87	$30.82 ▼ $68.73	$2.07B	0.77	400,040 shs	96,186 shs
OCUL Ocular Therapeutix	$11.86 -3.5%	$10.91	$5.78 ▼ $12.91	$2.07B	1.49	1.79 million shs	492,879 shs
ZVRA Zevra Therapeutics	$9.34 -1.1%	$10.56	$6.19 ▼ $13.16	$524.03M	1.87	755,841 shs	1.11 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	-9.41%	-19.23%	-8.70%	-45.65%
IRON Disc Medicine	0.00%	+0.82%	-0.43%	+27.40%	+22.14%
OCUL Ocular Therapeutix	0.00%	-2.54%	+0.74%	+68.49%	+35.02%
ZVRA Zevra Therapeutics	0.00%	+0.11%	-15.94%	+9.13%	+31.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IBRX ImmunityBio	2.5181 of 5 stars	3.6	1.0	0.0	3.3	1.7	0.6
IRON Disc Medicine	3.5445 of 5 stars	4.5	3.0	0.0	2.9	2.5	0.0
OCUL Ocular Therapeutix	4.0529 of 5 stars	3.5	3.0	4.1	3.6	0.8	0.0
ZVRA Zevra Therapeutics	3.4071 of 5 stars	4.5	3.0	0.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	3.20	Buy	$10.75	378.84% Upside
IRON Disc Medicine	3.09	Buy	$98.30	65.29% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	44.98% Upside
ZVRA Zevra Therapeutics	3.00	Buy	$23.71	154.01% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, IBRX, OCUL, and IRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$85.00 ➝ $90.00
8/18/2025	ZVRA Zevra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $18.00
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
7/25/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$14.74M	143.97	N/A	N/A	($0.57) per share	-3.94
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
OCUL Ocular Therapeutix	$56.66M	36.43	N/A	N/A	$2.01 per share	5.90
ZVRA Zevra Therapeutics	$23.61M	22.20	N/A	N/A	$0.74 per share	12.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$413.56M	-$0.48	N/A	N/A	N/A	-648.57%	N/A	-113.86%	11/11/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$4.47	N/A	N/A	N/A	N/A	-26.60%	-24.58%	11/11/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	11/13/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$0.21	N/A	46.68	N/A	4.33%	-112.40%	-37.67%	11/11/2025 (Estimated)

Latest ZVRA, IBRX, OCUL, and IRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IRON Disc Medicine	-$1.17	-$1.58	-$0.41	-$1.58	N/A	N/A
8/5/2025	Q2 2025	IBRX ImmunityBio	-$0.10	-$0.10	N/A	-$0.10	$21.95 million	$26.43 million
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	4.11	3.98
IRON Disc Medicine	0.05	32.11	32.11
OCUL Ocular Therapeutix	0.23	10.10	10.02
ZVRA Zevra Therapeutics	0.52	7.85	7.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
IRON Disc Medicine	83.70%
OCUL Ocular Therapeutix	59.21%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	76.79%
IRON Disc Medicine	3.64%
OCUL Ocular Therapeutix	2.30%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	590	945.26 million	219.39 million	Optionable
IRON Disc Medicine	30	34.77 million	33.50 million	Not Optionable
OCUL Ocular Therapeutix	230	174.00 million	169.99 million	Optionable
ZVRA Zevra Therapeutics	20	56.13 million	54.79 million	Optionable

ZVRA, IBRX, OCUL, and IRON Headlines

Recent News About These Companies

Zacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to Hold

August 22 at 9:59 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Sees Strong Trading Volume Following Insider Buying Activity

August 22 at 2:47 AM | americanbankingnews.com

Zevra Therapeutics rumor highlighted in Betaville blog

August 21, 2025 | msn.com

Zevra Therapeutics gains amid takeover speculation

August 21, 2025 | msn.com

Zevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 Shares

August 21, 2025 | insidertrades.com

Tourmaline Bio (NASDAQ:TRML) versus Zevra Therapeutics (NASDAQ:ZVRA) Head to Head Review

August 20, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Lower Earnings Estimates for ZVRA

August 17, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZVRA Q3 Earnings

August 17, 2025 | marketbeat.com

Q3 EPS Forecast for Zevra Therapeutics Increased by Analyst

August 17, 2025 | marketbeat.com

HC Wainwright Has Bearish Estimate for ZVRA FY2027 Earnings

August 16, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Cut Earnings Estimates for ZVRA

August 16, 2025 | americanbankingnews.com

Q3 EPS Estimate for Zevra Therapeutics Lifted by Analyst

August 16, 2025 | americanbankingnews.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

August 15, 2025 | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down on Analyst Downgrade

August 15, 2025 | marketbeat.com

JMP Securities Lowers Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00

August 15, 2025 | marketbeat.com

JMP Securities Has Lowered Expectations for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price

August 15, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPS

August 14, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Altium Capital Management LLC's Largest Position

August 14, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down Following Analyst Downgrade

August 14, 2025 | americanbankingnews.com

Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability

August 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, IBRX, OCUL, and IRON Company Descriptions

ImmunityBio NASDAQ:IBRX

$2.24 -0.07 (-2.81%)

Closing price 03:59 PM Eastern

Extended Trading

$2.27 +0.02 (+1.11%)

As of 04:04 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Disc Medicine NASDAQ:IRON

$59.47 -0.88 (-1.46%)

Closing price 03:59 PM Eastern

Extended Trading

$59.44 -0.03 (-0.05%)

As of 04:04 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Ocular Therapeutix NASDAQ:OCUL

$11.86 -0.44 (-3.54%)

Closing price 03:59 PM Eastern

Extended Trading

$11.86 +0.00 (+0.01%)

As of 04:04 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Zevra Therapeutics NASDAQ:ZVRA

$9.34 -0.10 (-1.10%)

Closing price 03:59 PM Eastern

Extended Trading

$9.43 +0.09 (+1.01%)

As of 04:04 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time